Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias(Moderna Therapeutics (United States)), Rituparna Das(Moderna Therapeutics (United States)), Bethany Girard(Moderna Therapeutics (United States)), Nichole McGhee(Moderna Therapeutics (United States)), Paul Bradley(Meridian Clinical Research), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xing Chen(Moderna Therapeutics (United States)), Jing Feng(Moderna Therapeutics (United States)), Xiaoying Shen(University of California, Los Angeles), Jacqueline M. Miller(Moderna Therapeutics (United States)), Darin K. Edwards(Moderna Therapeutics (United States)), Shishir Khetan(Meridian Clinical Research), Andrea Sutherland(Moderna Therapeutics (United States)), Jordan L. Whatley(Meridian Clinical Research), Lindsey R. Baden(Brigham and Women's Hospital), Xiaoping Zhao(Nanyang Technological University), Frank Eder(University of Maryland, Baltimore), David C. Montefiori(Duke University), Brandon Essink(Velocity Clinical Research (United States)), Adam Brosz(Meridian Clinical Research)
Cited by 77
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k